Literature DB >> 20402543

Economic content in medical journal advertisements for medical devices and prescription drugs.

D Clay Ackerly1, Seth W Glickman, Kevin A Schulman.   

Abstract

Previous studies of economic content in medical journal advertisements have not examined all types of economic content and have not included advertisements for medical devices. To examine trends in the economic content of medical device and pharmaceutical advertisements in medical journals. Three reviewers examined pharmaceutical and medical device advertisements in six leading medical journals from 1997 through 2006. Product characteristics, economic claims and evidence to support those claims were evaluated. Economic content appeared in 23.5% (561/2389) of pharmaceutical and device advertisements; 11.9% made market share claims and 12.7% made other economic claims. From 1997 through 2006, the percentage of medical device advertisements containing economic content declined from 26.7% to 6.7% (p = 0.02), whereas the percentage of pharmaceutical advertisements containing economic content remained stable (21.6-22.0%; p = 0.99). For pharmaceuticals, price claims declined significantly (15.7-4.2%; p < 0.01) and market share claims increased (2.8-11.5%; p = 0.09), and both consistently presented evidence (83% and 98%, respectively) while other types did not (e.g. 13.5% of formulary claims). Medical device economic claims differed from pharmaceutical economic claims; they made fewer market share claims (1.1% vs 12.8%) but more cost-effectiveness (6.5% vs 0.6%) and reimbursement (4.9% vs 0.8%) claims. Fewer than 2% of device advertisements with economic claims provided supporting evidence. The prevalence and type of economic content in pharmaceutical and device advertisements changed between 1997 and 2006, which may reflect evolving market dynamics, such as changes in reimbursement systems. Furthermore, the lack of supporting evidence in medical device advertisements and pharmaceutical formulary claims are potential areas of concern that require additional scrutiny by regulators and journal editors.

Mesh:

Substances:

Year:  2010        PMID: 20402543     DOI: 10.2165/11318780-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

1.  Pharmaceutical cost growth under capitation: a case study.

Authors:  M Chernew; M E Cowen; D M Kirking; D G Smith; P Valenstein; A M Fendrick
Journal:  Health Aff (Millwood)       Date:  2000 Nov-Dec       Impact factor: 6.301

2.  Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism?

Authors:  Dawn M Gencarelli
Journal:  NHPF Issue Brief       Date:  2002-06-07

3.  Economic messages in prescription drug advertisements in medical journals.

Authors:  Peter J Neumann; Kara Zivin Bambauer; Vijay Ramakrishnan; Kate A Stewart; Chaim M Bell
Journal:  Med Care       Date:  2002-09       Impact factor: 2.983

4.  US regulation of Advertising and promotional materials.

Authors:  Maria Donawa
Journal:  Med Device Technol       Date:  2006-05

5.  Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999.

Authors:  Jennifer A Palmer; Alison R Timm; Peter J Neumann
Journal:  J Manag Care Pharm       Date:  2008-10

6.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

7.  Patient-physician communication about out-of-pocket costs.

Authors:  G Caleb Alexander; Lawrence P Casalino; David O Meltzer
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

8.  Physician consideration of patients' out-of-pocket costs in making common clinical decisions.

Authors:  Hoangmai H Pham; G Caleb Alexander; Ann S O'Malley
Journal:  Arch Intern Med       Date:  2007-04-09

9.  Current and future developments in managed care in the United States and implications for Europe.

Authors:  Ronald Lagoe; Deborah L Aspling; Gert P Westert
Journal:  Health Res Policy Syst       Date:  2005-03-17

Review 10.  Physician awareness of drug cost: a systematic review.

Authors:  G Michael Allan; Joel Lexchin; Natasha Wiebe
Journal:  PLoS Med       Date:  2007-09       Impact factor: 11.069

View more
  1 in total

1.  US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research.

Authors:  Peter J Neumann; Pei-Jung Lin; Tom E Hughes
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.